Ectonucleoside triphosphate diphosphohydrolase 1 (ENTPDase1) (ENTPDase1)

Ectonucleoside triphosphate diphosphohydrolase 1 (ENTPDase1), historically characterized as Bovine ecto-ATPase, is a cell-surface enzyme that plays a pivotal role in regulating extracellular nucleotide concentrations by hydrolyzing ATP and ADP into AMP (Source: UniProt P55934). This enzyme was extensively studied in bovine aortic endothelial cells, where it was identified as a critical regulator of vascular homeostasis and a potent thromboregulator due to its ability to degrade ADP, a primary inducer of platelet aggregation (Source: PubMed: 1843547). By controlling the balance between pro-inflammatory ATP and immunosuppressive adenosine, ENTPDase1 acts as a metabolic rheostat in the purinergic signaling pathway. In modern drug discovery, the human ortholog (CD39) is a major target in immuno-oncology; inhibitors are designed to block the production of adenosine in the tumor microenvironment, thereby restoring the activity of cytotoxic T-cells and natural killer cells (Source: PubMed: 31515460). While bovine-derived enzymes were instrumental in early biochemical mapping and inhibitor screening, current therapeutic efforts focus on humanized monoclonal antibodies and small molecules for treating cancer and inflammatory disorders.

Other names

CD39Bovine ecto-ATPaseEcto-apyraseATPDaseNTPDase1Ecto-ATP diphosphohydrolase 1Bovine aortic ecto-ATPase

Inhibition of the enzymatic hydrolysis of extracellular ATP and ADP to AMP, thereby modulating the purinergic signaling cascade and preventing the formation of immunosuppressive adenosine (Source: PubMed: 31515460).